Wisdom Bioscience, Inc. announced the formation of a scientific advisory board following the close of an initial funding round. The board includes Giulia Kennedy, Ph.D.; Arnold Levine, Ph.D.; John Sninsky, Ph.D.; Martin Goldberg, Ph.D.; and Professor Tin Tin Su, Ph.D., who will provide scientific and clinical guidance as the company advances its product pipeline and expands its services.
According to the company, the advisory board members bring experience in cell-free DNA research, oncology screening, and molecular diagnostics across research, development, and commercialization.
Giulia Kennedy, Ph.D., is co-founder and chief scientific officer of PinkDx, Inc., a molecular diagnostic company focused on women’s gynecological cancers. Prior to co-founding PinkDx, she served as chief scientific officer and chief medical officer of Veracyte, Inc., where she led the development and commercialization of eight genomic diagnostic tests.
Arnold Levine, Ph.D., has conducted research for more than 35 years in molecular oncology, genomics, tumor suppressor gene functions, and epidemiological contributions to cancer formation. His recent work has focused on immune responses to cancers, cancer therapies, and prevention.
John Sninsky, Ph.D., has worked in senior management roles at laboratory-developed test and in vitro diagnostic organizations. His experience includes translating scientific innovation into reimbursed clinical practice for infectious and genetic diseases, oncology, and solid organ transplantation. His technology experience includes development and commercialization of polymerase chain reaction testing, next-generation sequencing of the human genome, genome-wide association studies, and liquid biopsies.
Martin Goldberg, Ph.D., is a distinguished scientific fellow at Seer, Inc. He has more than 30 years of experience in the life sciences tools industry, including work with research-use and diagnostic platforms across genomics and proteomics, as well as advising early-stage companies.
Professor Tin Tin Su, Ph.D., has more than 25 years of experience in chemical genetics and tissue regeneration after radiation damage using Drosophila and human cancer models, according to the company.
Founded in 2024, Wisdom Bioscience focuses on integrating genomic technologies into routine dental care for oral cancer screening. It has developed a platform for non-invasive detection of oral cancer designed for use during dental appointments. The test uses a mouth swab and next-generation sequencing technology with the goal of enabling earlier detection in clinical settings where patients already receive routine care.
The company stated that the funding round included investment from Stephen Quake and Jay Flatley. Proceeds from the financing will support continued clinical validation and preparations for a commercial launch later this year, the company said.
“We have assembled a highly accomplished group of scientific leaders whose collective expertise will be instrumental in guiding both our product development and long-term strategy,” said Aditya Rajagopal, Ph.D., co-founder and chairman of the board, Wisdom Bioscience.
Hayden Jeffreys, co-founder and chief executive officer, Wisdom Bioscience, added: “The formation of our SAB, alongside the support of such respected investors represents a strong endorsement of our vision and our ambition to transform oral cancer diagnostics and screening, particularly as we progress towards our next funding round.”
More information is available at https://wisdombioscience.com/.
